Clinical Trial

A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases

Name: A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases — clinical trial record (NCT07265206)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of HY001N cell injection in the treatment of patients with relapsed/refractory Neurological Autoimmune Diseases.

Trial Details

NCT Number	NCT07265206
Lead Sponsor	Juventas Cell Therapy Ltd. Collaborators: Beijing Tiantan Hospital
Conditions	Neurological Autoimmune Diseases
Enrollment	15 participants
Start Date	2025-12-30
Primary Completion	2026-12-30 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-04